Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS)

Crump, 2017, Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study, Blood, 130, 1800, 10.1182/blood-2017-03-769620 Friedberg, 2011, Relapsed/refractory diffuse large B-cell lymphoma, Hematology Am Soc Hematol Educ Program, 2011, 498, 10.1182/asheducation-2011.1.498 Dang, 2018, Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab versus chemotherapy plus rituximab for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma, Br J Haematol, 182, 583, 10.1111/bjh.14820 Mounier, 2011, Rituximab plus gemcitabine and oxaliplatin in patients with refractory/relapsed diffuse large B-cell lymphoma who are not candidates for high-dose therapy. A phase II Lymphoma Study Association trial, Haematologica, 98, 1726, 10.3324/haematol.2013.090597 Halwani AS, Rasmussen KM, Patil V, et al. Treatment practices and outcomes in older adults with relapsed/refractory diffuse large B-cell lymphoma treated in the Veterans Health Administration. Poster presented at American Society of Hematology—60th Annual Meeting; San Diego, CA, USA; Dec 1–4, 2018. Gopal, 2014, PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma, N Engl J Med, 370, 1008, 10.1056/NEJMoa1314583 Dreyling, 2017, Phosphatidylinositol 3-kinase inhibition by copanlisib in relapsed or refractory indolent lymphoma, J Clin Oncol, 35, 3898, 10.1200/JCO.2017.75.4648 Mehta, 2015, Development and integration of antibody-drug conjugate in non-Hodgkin lymphoma, Curr Oncol Rep, 17, 41, 10.1007/s11912-015-0466-9 Dornan, 2009, Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma, Blood, 114, 2721 Li, 2013, DCDT2980S, an anti-CD22-monomethyl auristatin E antibody–drug conjugate, is a potential treatment for non-Hodgkin lymphoma, Mol Cancer Ther, 12, 1255, 10.1158/1535-7163.MCT-12-1173 Pfeifer, 2015, Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypes, Leukemia, 29, 1578, 10.1038/leu.2015.48 Palanca-Wessels, 2015, Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study, Lancet Oncol, 16, 704, 10.1016/S1470-2045(15)70128-2 Advani, 2017, Phase I study of the anti-CD22 antibody-drug conjugate pinatuzumab vedotin with/without rituximab in patients with relapsed/refractory B-cell non-Hodgkin lymphoma, Clin Cancer Res, 23, 1167, 10.1158/1078-0432.CCR-16-0772 Fayad, 2013, Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab, J Clin Oncol, 31, 573, 10.1200/JCO.2012.42.7211 Cheson, 2007, Revised response criteria for malignant lymphoma, J Clin Oncol, 25, 579, 10.1200/JCO.2006.09.2403 Coiffier, 2016, A phase II, single-arm, multicentre study of coltuximab ravtansine (SAR3419) and rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma, Br J Haematol, 173, 722, 10.1111/bjh.13992 LaPointe, 2013, Effects of eribulin, vincristine, paclitaxel and ixabepilone on fast axonal transport and kinesin-1 driven microtubule gliding: implications for chemotherapy-induced peripheral neuropathy, Neurotoxicology, 37, 231, 10.1016/j.neuro.2013.05.008 Younes, 2012, Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma, J Clin Oncol, 30, 2183, 10.1200/JCO.2011.38.0410 Bari, 2017, A multicenter phase II study of twice-weekly bortezomib plus rituximab in patients with relapsed follicular lymphoma: long-term follow-up, Acta Haematol, 137, 7, 10.1159/000449052 Lu, 2017, Time-to-event analysis of polatuzumab vedotin-induced peripheral neuropathy to assist in the comparison of clinical dosing regimens, CPT Pharmacometrics Syst Pharmacol, 6, 401, 10.1002/psp4.12192 Lu D, Jin J, Gibiansky L, et al. Population pharmacokinetics and exposure-response assessment of polatuzumab vedotin (anti-CD79b antibody drug conjugate) in patients with relapsed/refractory B-cell lymphoma: interim analysis results. Poster presented at American Society for Clinical Pharmacology and Therapeutics—116th Annual Meeting; New Orleans, LA, USA; March 3–7, 2015. Sehn, 2017, Prognostic impact of BCL2 and MYC expression and translocation in untreated DLBCL: results from the phase III GOYA study, Hematol Oncol, 35, 131, 10.1002/hon.2437_121 Chen, 2015, CD30 downregulation, MMAE resistance, and MDR1 upregulation are all associated with resistance to brentuximab vedotin, Mol Cancer Ther, 14, 1376, 10.1158/1535-7163.MCT-15-0036 Sehn, 2017, Addition of polatuzumab vedotin to bendamustine and rituximab (BR) improves outcomes in transplant-ineligible patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) versus BR alone: results from a randomized phase 2 study, Blood, 130, 2821 Tilly, 2017, POLA-R-CHP: polatuzumab vedotin combined with rituximab, cyclophosphamide, doxorubicin, prednisone for patients with previously untreated diffuse large B-cell lymphoma, Hematol Oncol, 35, 90, 10.1002/hon.2437_79